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H19 lncRNA alters DNA methylation genome wide
by regulating S-adenosylhomocysteine hydrolase
Jichun Zhou1,2,*, Lihua Yang1,3,*, Tianyu Zhong1,4,*, Martin Mueller1,5, Yi Men1,6, Na Zhang7,
Juanke Xie1,8, Karolyn Giang9, Hunter Chung9, Xueguang Sun9, Lingeng Lu10, Gordon G. Carmichael7,
Hugh S. Taylor1 & Yingqun Huang1
DNA methylation is essential for mammalian development and physiology. Here we
report that the developmentally regulated H19 lncRNA binds to and inhibits S-adenosylho-
mocysteine hydrolase (SAHH), the only mammalian enzyme capable of hydrolysing
S-adenosylhomocysteine (SAH). SAH is a potent feedback inhibitor of S-adenosylmethionine
(SAM)-dependent methyltransferases that methylate diverse cellular components, including
DNA, RNA, proteins, lipids and neurotransmitters. We show that H19 knockdown activates
SAHH, leading to increased DNMT3B-mediated methylation of an lncRNA-encoding gene
Nctc1 within the Igf2-H19-Nctc1 locus. Genome-wide methylation proﬁling reveals methylation
changes at numerous gene loci consistent with SAHH modulation by H19. Our results
uncover an unanticipated regulatory circuit involving broad epigenetic alterations by a single
abundantly expressed lncRNA that may underlie gene methylation dynamics of development
and diseases and suggest that this mode of regulation may extend to other cellular
components.
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G
ene methylation (5-methyl-cytosine), accomplished by the
joint action of three S-adenosylmethionine (SAM)-
dependent DNA methyltransferases (DNMT1, DNMT3A
and DNMT3B), plays a critical role in mammalian development
and physiology. Altered gene methylation can cause develop-
mental abnormalities and diseases. Being a dynamic process,
methylation at a given gene locus is determined not only by the
activity of the DNMTs, which have little sequence speciﬁcity, but
also by local chromatin structure and modiﬁcations (that is,
histone methylation and acetylation) that affect their accessi-
bility1–3. DNMTs can also be targeted to speciﬁc gene loci via
direct association with transcription factors4. Recent discoveries
have marked long noncoding RNAs (lncRNAs) as new important
players in DNA methylation regulation. lncRNAs can act in cis
(at their site of transcription) or in trans (diffusing to other loci)
to recruit chromatin-modifying complexes such as the Polycomb
repressive complex 2 (PRC2) to affect chromatin structure
and modiﬁcations5,6. In addition, the noncoding ecCEBPA
transcript encoded within the CEBPA gene locus binds to
DNMT1 and prevents CEBPA gene methylation7. This
methylation blockade by DNMT1-interacting RNAs may extend
to other genomic loci, although each of these RNAs acts locally,
not genome wide7.
SAM-dependent methylation is central to the regulation
of numerous biological processes. A wide spectrum of
cellular components, including DNA, RNA, lipids, proteins and
neurotransmitters, is subjected to methylation by SAM-depen-
dent methyltransferases. SAM serves as the methyl-group donor
during transmethylation reactions, yielding S-adenosylhomo-
cysteine (SAH) as a by-product, which is a strong feedback
inhibitor of most SAM-dependent transmethylation reactions. In
mammals, S-adenosylhomocysteine hydrolase (SAHH) is the only
known enzyme that catalyses the hydrolysis of SAH to
homocysteine and adenosine, thereby relieving the inhibition8.
A complete loss of SAHH is embryonic lethal9, whereas SAHH
dysfunction results in numerous pathological consequences
such as developmental abnormalities, neurovascular disorders,
myopathy, cancer and childhood death10,11. Furthermore,
inhibition of SAHH elicits antiviral effects12. Despite the pivotal
roles that SAHH plays in a broad range of biological processes,
how its activity is regulated remains poorly understood. Being an
extraordinarily conserved enzyme (the human and mouse SAHH
proteins share 97% identity), SAHH functions as a tetramer with
cofactor NADþ /NADH bound to each subunit. Interaction with
adenosine or copper inhibits SAHH activity8. Recently, lysine
acetylation of SAHH has been reported to alter the structure and
activity of this enzyme13. However, the biological signiﬁcance of
regulation of SAHH by these molecules and by acetylation is
unclear. In addition, the possibility of SAHH regulation by other
mechanisms remains to be explored.
The developmentally regulated imprinted H19, together with
its co-regulated gene Igf2, plays important roles in embryo
development and growth control and has been associated with
human genetic disorders14. H19 is highly expressed in human and
mouse placentas and fetal tissues as well as in a subset of post-
natal and adult tissues including skeletal muscle15,16, heart17–19,
haematopoietic stem cells20 and endometrium21. In addition,
aberrant H19 expression has been detected in diverse human
malignancies22. H19 encodes a polyadenylated lncRNA of
B2.6 kb, which is predominantly cytoplasmic with a minor
fraction also found in the nucleus14,23. H19 is a multifunctional
lncRNA that has activities both in the nucleus and in the
cytoplasm. Using genetically modiﬁed mouse models and cell
culture systems, H19 has been shown to interact with the methyl-
CpG-binding domain protein 1, that recruits repressive histone
marks to imprinted network genes to inhibit transcription,
thereby contributing to embryo growth regulation23. H19 also
serves as a microRNA precursor for miR-675 that acts to inhibit
placental growth24, maintain adult haematopoietic stem cells20,
stimulate skeletal muscle differentiation and regeneration15 and
promote oncogenesis25,26. The oncogenic property of H19 is also
attributed to its full-length processed transcript that targets PRC2
(through binding to EZH2, the histone lysine methyltransferase
component of PRC2) to genes that promote cancer metastasis27.
In addition to these nuclear functions, H19 directly binds to the
RNA-binding protein K homology-type splicing-regulatory
protein in the cytoplasm to control myogenic differentiation28.
Further, H19 acts as a molecular sponge for microRNA let-7,
contributing to the regulation of muscle differentiation29, glucose
metabolism16, tumour metastasis30 and endometrium
development21.
In this report we show that H19 binds to SAHH and inhibits its
function both in vivo and in vitro. This interaction prevents
SAHH from hydrolysing SAH that blocks DNA methylation by
DNMT3B at numerous genomic loci. This differs from what has
been described before for other lncRNAs. We propose that this
novel epigenetic regulatory mechanism may underlie the DNA
methylation dynamics associated with development and diseases
and that this mode of regulation may extend to other cellular
components.
Results
SAHH interacts with H19 in ribonucleoprotein complexes.
In search of possible new functions of H19, we performed
RNA afﬁnity chromatography using an S1 aptamer-tagged H19
(pH19-S1; untagged pH19 or S1 tag only as negative controls)29
to identify H19-associated protein components (Fig. 1a). The
indicated plasmids were each transfected into HEK293 cells that
do not express endogenous H19. Puriﬁed ribonucleoproteins
(RNPs) were resolved using SDS–PAGE, followed by Coomassie
blue staining. A protein band with a molecular size of B48 kDa
that was speciﬁc to pH19-S1 (Fig. 1b, left lane marked with a red
arrow) was cut out and subjected to protein mass spectrometry
analysis. A number of proteins were identiﬁed including SAHH,
nuclear factor 45, propionyl-CoA carboxylase, methylcrotonoyl-
CoA carboxylase, mitochondrial elongation factor Tu (EF-Tu),
creatine kinase B-type, 40S ribosomal protein SA, multifunctional
protein ADE2 isoform 2 and heterogeneous nuclear RNP D.
We decided to focus on SAHH for several reasons. First,
SAHH belongs to a large family of proteins that use
NAD(P)þ /NAD(P)H as cofactors via the dinucleotide-binding
Rossmann-fold (a protein structural motif that binds nucleotides,
especially the cofactor NAD)8. Second, a dozen enzymes
harbouring the Rossmann-fold have been reported to bind
polyadenylated RNAs in HeLa cells31. Third, the Rossmann-fold
is an RNA-binding domain for both glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) and
mediates their binding to AU- and U-rich RNA elements32,33.
Finally, SAHH is the only mammalian enzyme capable of
breaking down SAH, a potent product inhibitor of most
SAM-dependent transmethylation reactions.
Western blot analysis of afﬁnity-puriﬁed RNPs revealed
association of SAHH with pH19-S1 but not with pH19 (Fig. 1c,
top blot, compare lane 3 with lane 4). The RNA-binding protein
HuR, previously shown to bind H19 (ref. 24), was also in complex
with pH19-S1 under the same conditions (middle blot, lane 4),
while beta-tubulin was not (bottom blot, lane 4). Taken together,
these results supported the notion that the SAHH–H19 interac-
tion was speciﬁc. Next, we performed RNA immunoprecipitation
(RIP) experiments using a monoclonal antibody speciﬁc to SAHH
with myotubes derived from mouse myoblasts to determine
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whether SAHH associates with endogenous H19 Both H19 and
SAHH were predominantly localized to the cytoplasm of the
myotubes (Supplementary Fig. 1). We observed a nearly eightfold
enrichment of H19 in SAHH-containing RNPs relative to control
IgG immunoprecipitates (Fig. 1d, left column), whereas GAPDH
mRNA, expressed at approximately fourfold higher level
than that of H19 (Fig. 1e), did not detectably associate with the
SAHH-containing RNPs (Fig. 2e, right column). The speciﬁcity of
the monoclonal SAHH antibody was conﬁrmed using RIP and
western blot analysis (Fig. 1f). As expected, we observed
preferential enrichment of H19 in HuR-containing RNPs using
a polyclonal HuR antibody under the same conditions
(Supplementary Fig. 2). Collectively, we concluded that SAHH
interacts with H19 in RNPs in both human and mouse cells.
H19 knockdown activates SAHH. What could be the functional
signiﬁcance of the SAHH–H19 interaction? We hypothesized that
binding to H19 might interfere with SAHH’s ability to hydrolyse
SAH to homocysteine and adenosine. To test this possibility, we
used the well-characterized, imprinted Igf2-H19-Nctc1 gene locus
in mouse skeletal muscle cells as a model system. The regulation
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Figure 1 | SAHH interacts with H19 in RNPs. (a) Schematic outline of puriﬁcation of H19-associated RNPs and protein component identiﬁcation. (b) Image
of a Commassie staining gel with protein size markers (in kDa) labelled on the left. The SAHH protein band is marked with a red arrow. (c) pH19-S1 or pH19
were transfected into HEK293 cells, followed by afﬁnity puriﬁcation as outlined in a. Puriﬁed RNPs were resolved using 10% SDS–PAGE, followed by
western blot analysis using rabbit polyclonal antibodies speciﬁc for SAHH (top), HuR (middle) or beta-tubulin (bottom). Ten percent input was loaded on
lanes 1 and 2. Molecular marker positions in kDa are shown on the right. (d) RIP with mouse monoclonal anti-SAHH or pre-immune IgGs from myotube
extracts. RNA levels in immunoprecipitates were determined using reverse transcription and qPCR. Levels of H19 and GAPDH mRNA are presented as fold
enrichment in anti-SAHH relative to IgG immunoprecipitates. Student’s t-tests were used to compare differences between quantitative variables. Numbers
are mean±s.d. (n¼ 3). **Po0.01. (e) Relative RNA levels of H19 and GAPDH in myotubes. (f) Immunoprecipitation using monoclonal anti-SAHH (lane 2)
or IgG (lane 3), followed by western blot analysis using a rabbit polyclonal anti-SAHH. Five percent input was loaded in lane 1. The SAHH band is marked.
(g) Cartoon depiction of the Igf2-H19-Nctc1 locus (not drawn to scale). The three exons of Nctc1 are marked as red boxes, and the CME as a blue dot. The
transcription start site of Nctc1 is set as 0 kb.
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of expression of these genes requires a shared enhancer that is
located 20 kb downstream of H19 (or 100 kb downstream of
Igf2)34. This enhancer functions in an unique manner in that it
needs both a short core element of B300 bp (called core muscle
enhancer, or CME) and transcription of the lncRNA-encoding
gene Nctc1 within the same enhancer region35 (Fig. 1g). The CME
resides within the gene body of Nctc1 in the second intron and is
7 kb downstream of the Nctc1 promoter. In adult muscle cells
where Nctc1 has lost its imprinting36, activation of the Nctc1
promoter by CME has a negative impact on H19 expression.
Promoter competition (the Nctc1 promoter recruits RNA
polymerase II (RNAP) for its own transcription at the expense
of activation of the H19 promoter) has been proposed as a
possible underlying mechanism36. Indeed, in myotubes
RT–qPCR
R
el
at
ive
 R
N
A 
le
ve
l 1.5
1.0
0.5
0.0
siCon
siH19
**
H19 Sahh R
el
at
ive
 S
AH
H 
ac
tiv
ity 1.5
1.0
0.5
0.0
In vivo SAHH activity
**
siCon siH19
1.5
1.0
0.5
0.0
**
siCon siH19
QMSP
R
el
at
ive
 D
M
R
 m
et
hy
la
tio
n
2.0
Sequence of DMR
chr7
DMR
142551263 142551245 142551206
74% versus 50%
1.5
1.0
0.5
0.0
RT–qPCR
siCon
siH19
siH19+siDnmt3b
R
el
at
ive
 R
N
A 
le
ve
l **
** **
H19 Dnmt3b
Western
si
Co
n
si
H
19
si
H
19 +
si
D
nm
t3
b
DNMT3B
TUBB
% 100
100
97 30
50
1.5
1.0
0.5
0.0
2.0
QMSP
R
el
at
ive
 D
M
R
 
m
e
th
yla
tio
n
* *
siCon siH19 siH19
+
siDnmt3b
DNMT3B ChIP
0.8
0.6
0.4
0.2
0.0
%
 in
pu
t
si
Co
n
si
H
19
Nctc1
DMR
NS
DNMT3B
lgG
%
 in
pu
t
si
Co
n
si
Co
n
si
Co
n
si
H
19
si
H
19
si
H
19
Nctc1
Exon 1 Neg
H19
Exon 1
lgG
RNAP ChIP
4
3
2
1
0
**
**
RNAP
1.5
1.0
0.5
0.0
2.0 siCon
siH19
**
**
RT–qPCR
R
el
at
ive
 R
N
A 
le
ve
l
H19 Nctc1
a b c
d
e f g
h i j
Figure 2 | DNMT3B contributes to SAHH-mediated, H19-dependent methylation change in CME. (a) Myotubes were transfected with siCon or siH19,
followed by RNA extraction and RT–qPCR analysis 48 h later. Relative RNA levels of H19 and Sahh are presented. (b) In vivo SAHH activity assessed 48 h
post-siRNA transfection, as described in a. (c) Relative DMR methylation assessed using QMSP. (d) Sequence of the DMR ampliﬁed using the QMSP
primers, with the differentially methylated cytosine highlighted in red. Numbers above the sequence mark positions of the indicated nucleotides in the
chromosome. Numbers below indicate percentage of methylation in siH19 (left) versus siCon (right) cells, as determined using genome-wide methylation
analysis. (e) Myotubes were transfected with siCon, siH19 or siH19 plus siDnmt3b, followed by RNA extraction and RT–qPCR analysis 48 h post
transfection. Relative RNA levels of H19 and Dnmt3b are presented. (f) Western blot results representative of three independent transfection experiments
(performed as described in e) are shown. Antibodies speciﬁc for DNMT3B and beta-tubulin were used on the top and bottom blots, respectively. Numbers
underneath the blots indicate DNMT3B protein levels after normalization against TUBB loading controls with that in siCon cells arbitrarily set as 100%.
(g) Myotubes were transfected with siCon, siH19 or siH19 plus siDnmt3b. DMR methylation was assessed 48 h post transfection using QMSP.
(h) DNMT3B occupation at CME. Myotubes were transfected with siCon or siH19. ChIP analysis was performed 48 h later using anti-DNMT3B antibody to
evaluate binding of DNMT3B at the DMR. ns, not statistically different. (i) Association of activated RNAP with Nctc1 and H19. Myotubes were transfected as
described in h. ChIP analysis was performed using anti-RNAP antibody. (j) Relative RNA levels of H19 and Nctc1 following siRNA transfection. Student’s
t-tests were performed to compare differences between quantitative variables. Numbers are mean±s.d. (n¼ 3). *Po0.05, **Po0.01.
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differentiated in vitro from mouse myoblasts Nctc1 expression
was inversely correlated with that of H19. Consistent with the
promoter competition model, association of RNAP with Nctc1
was also inversely correlated with H19 transcriptional
activation36. Intriguingly, the CME contains a 219-bp CpG
island with unknown function. We decided to use this
well-characterized myotube system, where a negative impact of
Nctc1 promoter activity on H19 transcription has been
demonstrated36, to test the hypothesis that the SAHH–H19
interaction may affect CME methylation, which in turn inﬂuences
the transcriptional activity of Nctc1 and H19.
Thus, we downregulated H19 using an H19-speciﬁc short
interfering RNA (siRNA; siH19 (refs 16,29)) in myotubes
differentiated from mouse myoblasts, followed by in vivo
SAHH activity assessment using homocysteine as a readout37.
When the H19 level was reduced toB20% of the control (Fig. 2a,
left column) without signiﬁcantly affecting the level of SAHH
mRNA (right column), an B20% increase in SAHH activity was
observed (Fig. 2b). These results supported the view that H19
association inhibits SAHH’s ability to hydrolyse SAH, a strong
inhibitor of SAM-dependent methyltransferases including
DNMTs. We hypothesized that increased SAHH activity would
activate DNMTs, which otherwise would be inhibited by SAH,
leading to increased gene methylation. Indeed, we observed a 30%
increase in a differentially methylated region (DMR) within the
CME as determined by quantitative methylation-speciﬁc PCR
(QMSP) analysis (Fig. 2c). The PCR primers were designed to
cover this DMR based on our single-nucleotide resolution
genome-wide DNA methylation analysis (Fig. 2d, and see
below). Primers that cover another DMR (DMR-2) of CME
showed similar results (Supplementary Fig. 3). Next, we wanted
to test whether DNMT3B might be responsible for this increased
methylation. It was previously reported that in human skeletal
muscle cells the enzymatic activity (but not the protein level) of
DNMT3B increased in response to free fatty acids, resulting in
promoter hypermethylation of PGC-1a (ref. 38). Further, recent
genome-wide DNA methylome studies revealed a strong
association of DNMT3B with gene body methylation and its
positive correlation with gene expression1,39. Thus, CME
methylation was evaluated in the presence of double siRNA
knockdown. In the H19/Dnmt3b double knockdown group,
Dnmt3b was silenced by B40% at the RNA (Fig. 2e, right
column) andB70% at the protein levels (Fig. 2f, top blot). While
H19 single knockdown expectedly increased CME methylation
(Fig. 2g, compare middle bar with left bar) without altering the
DNMT3B protein level (Fig. 2f, top blot, compare middle lane
with left lane), the double knockdown restored methylation to the
control level (Fig. 2g), suggesting that DNMT3B contributed to
increased CME methylation induced by H19 knockdown. A
second siRNA (siDnmt3b-2) targeted to a different region of
Dnmt3b produced similar results (Supplementary Fig. 4),
conﬁrming the speciﬁcity of the Dnm3b siRNA effects. Further,
we carried out chromatin immunoprecipitation (ChIP) analysis
using a DNMT3B antibody shown to be highly speciﬁc for
DNMT3B in a genome-wide ChIP study1. Results revealed no
signiﬁcant change in DNMT3B occupancy at the DMR when H19
was downregulated (Fig. 2h), although a readily detectable change
in RNAP association with Nctc1 was observed under the same
conditions (see below). These results suggested that it was the
activity and not the chromatin residence of DNMT3B that was
responsible for the methylation change. This result is in line with
a previous report showing that a change in the enzymatic activity
of DNMT3B alone was sufﬁcient to induce hypermethylation of
PGC-1a in human skeletal muscle cells38. Collectively, these
results suggested that reducing H19 level de-represses SAHH and
enables it to act on SAH, thereby relieving inhibition of DNMT3B
by SAH and allowing DNMT3B to methylate CME.
CME methylation correlates with enhanced Nctc1 transcription.
To determine the effect of CME methylation on Nctc1 transcrip-
tion, we performed ChIP analysis using an anti-Ser-5(P)-RNAP
antibody that speciﬁcally recognizes activated RNAP as previously
described35,36. We compared binding of activated RNAP to Nctc1
between control siRNA (siCon)- and siH19-transfected myotubes
to assess relative transcription activity of Nctc1 (refs 35,36). We
observed an approximately fourfold enrichment in RNAP at Nctc1
in siH19- versus siCon-transfected myotubes (Fig. 2i), suggesting
an increase in Nctc1 transcription that was further supported
by the concomitant increase in the Nctc1 RNA level (Fig. 2j).
This positive correlation between CME methylation and
Nctc1 transcription was not surprising because increased gene
body methylation has been associated with increased trans-
cription1,3,39,40. We further noted a signiﬁcant decrease in RNAP
association with H19 in siH19-transfected myotubes (Fig. 2i,
middle column, compare right green bar with left green bar). These
results recapitulated the previously reported observation showing
an inverse relationship of transcriptional activity between Nctc1
and H19 (ref. 36) and suggested a novel functional role of CME
methylation in the regulation of Nctc1 and H19.
SAHH is required for H19-dependent CME methylation change.
To provide further evidence that increased CME methylation
induced by H19 knockdown was indeed mediated by SAHH,
double knockdown experiments using a Sahh-speciﬁc siRNA10
were carried out. In the H19/Sahh double knockdown cells,
Sahh was silenced by B60% at both the RNA (Fig. 3a, right
column) and protein levels (Fig. 3b, top blot). While H19 single
knockdown increased methylation, H19/Sahh double knockdown
abrogated this effect (Fig. 3c). The abrogation effect was also
observed when a pharmacological SAHH inhibitor D-Eritadenine
(DEA; Supplementary Fig. 5)41,42 was used (Fig. 3c). These results
further supported the notion that SAHH is required for
H19-mediated CME methylation change.
As increased CME methylation following H19 knockdown
correlated with increased Nctc1 transcription (Fig. 2g–j), we
predicted that H19 and Sahh double knockdown would reverse
this effect, given that increased CME methylation was dependent
on SAHH activation (Fig. 3c). Consistent with our earlier
observations (Fig. 2i, left column; and Fig. 2j, right column),
H19 single knockdown increased RNAP association with Nctc1
(Fig. 3d, left column, compare middle green bar with left green
bar) with a concomitant increase in the Nctc1 RNA level (Fig. 3e,
compare middle bar with left bar). In the H19 and Sahh double
knockdown cells, RNAP association with Nctc1 was signiﬁcantly
reduced compared with that in the H19 single knockdown cells
(Fig. 3d, left column, compare right green bar with the middle
green bar), and there was a decrease in the Nctc1 RNA level as
well (Fig. 3e). Moreover, the inverse relationship of RNAP
association between Nctc1 and H19 was lost in the double
knockdown cells (Fig. 3d, compare between the left and middle
columns). Collectively, these results strongly suggested that H19
induced CME methylation change through the action of SAHH,
which in turn affected the transcription of Nctc1 and H19.
U-rich element binding inhibits SAHH activity in vitro.
To further delineate the molecular nature of SAHH–H19
interaction, we took an in vitro approach to map binding sites
of SAHH on H19. Both GAPDH and LDH bind to AU- and
U-rich RNA elements via the Rossmann-fold32,33. SAHH has a
Rossmann-fold that binds cofactor NADþ , which is required
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for maintaining its quaternary structure and catalytic function8.
We hypothesized that SAHH may bind U-rich elements (URE),
as we noticed stretches of UREs ﬂanked by C or G near the
30-end of both human and mouse H19 (Fig. 4a). To test this
hypothesis, we performed electrophoretic mobility shift assays
(EMSAs) using puriﬁed recombinant human SAHH protein
(rSAHH) and 30-end biotin-labelled H19 RNA fragments. At
low rSAHH concentrations, only one complex (complex 1)
formed with both human (hURE) and mouse (mURE)
fragments (Fig. 4b, top two panels on the left). As rSAHH
concentration rose, an additional complex (complex 2)
appeared, suggesting simultaneous binding of more than one
molecule of rSAHH to multiple U-rich sequences. We estimated
the Kd values of rSAHH binding to the human and mouse UREs
to be 0.44 and 0.46 mM, respectively (Fig. 4b, bottom panel),
similar to the Kd value of LDH for the granulocyte–macrophage
colony-stimulating factor RNA AU-rich element, which was
reported to be 0.5 mM (ref. 33). The apparently slightly lower
Kd value of hURE was also reﬂected by competition experiments
showing that unlabelled hURE competed better for binding to
rSAHH than the unlabelled mURE (Fig. 4c, left two panels).
A non-U-rich fragment (hNSE) randomly chosen from human
H19 failed to efﬁciently compete for rSAHH binding (Fig. 4c,
third panel), which was consistent with its poor rSAHH-binding
afﬁnity (Fig. 4b). Further, the poly(U) ribohomopolymers
exhibited the highest activity in reducing complex formation
(Fig. 4c, fourth panel). Together, these results showed that
puriﬁed rSAHH was capable of direct binding to UREs in both
human and mouse H19 in vitro.
As H19 binds and inhibits SAHH activity in vivo (Figs 1c,d
and 2b), we tested effects of H19 fragments on the ability
of rSAHH to hydrolyse SAH in vitro. Both hURE and
mURE inhibited the hydrolytic activity of rSAHH in a
dose-dependent manner, whereas hNSE did not (Fig. 4d). This
was in line with the observation that both UREs had
signiﬁcantly higher afﬁnity for rSAHH than hNSE (Fig. 4b,c).
As expected, poly(U) also efﬁciently inhibited rSAHH activity
(Fig. 4d). Combined with our in vivo data (Figs 1c,d and 2b),
these results strongly support our hypothesis that SAHH
binding to H19 interferes with its ability to hydrolyse
SAH in vivo.
H19-dependent SAHH inhibition exerts global effects. As
SAHH can potentially affect SAM-dependent methyltransferases
other than DNMT3B, one would predict that H19 knockdown
would lead to global DNA methylation changes. Methylation at a
particular cytosine residue within a gene locus is inﬂuenced both
by the activity of DNMTs and by other epigenetic marks that
affect their accessibility1–3. SAHH activity change could not only
directly affect the activity of DNMTs, but also other epigenetic
marks, which in turn might indirectly affect gene methylation.
Further, not all methyltransferases display an equal sensitivity to
SAHH inhibition8. Thus, increased SAHH activity as a result of
H19 knockdown is expected to produce three different outcomes:
some genomic loci would become hypermethylated; some
hypomethylated; and some would not change, relative to
control knockdown.
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Figure 3 | SAHH is required for H19-dependent alteration in CME methylation and Nctc1 transcription. (a) Myotubes were transfected with siCon, siH19
or siH19 plus siSahh, followed by RNA extraction and RT–qPCR analysis 48 h later. Relative RNA levels of H19 and Sahh are presented. (b) Western blot
results representative of three independent transfection experiments (performed as described in a) are shown. Antibodies speciﬁc for SAHH and beta-actin
were used on the top and bottom blots, respectively. Numbers indicate SAHH protein levels after normalization against beta-actin loading controls with
levels in siCon cells arbitrarily set as 100%. (c) Myotubes were transfected with siCon, siH19, siH19 plus siSahh or siH19 plus incubation with 10mM of DEA
20h post transfection. DMR methylation was assessed 48 h post transfection using QMSP. (d) Association of activated RNAP at Nctc1 and H19. Myotubes
were transfected with siCon, siH19 or siH19 plus siSahh. ChIP analysis was performed 48 h post transfection. (e) Relative Nctc1 RNA levels measured 48 h
post transfection, as described in d. Student’s t-tests were performed to compare differences between quantitative variables. Numbers are mean±s.d.
(n¼ 3). **Po0.01.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10221
6 NATURE COMMUNICATIONS | 6:10221 | DOI: 10.1038/ncomms10221 | www.nature.com/naturecommunications
As a proof-of-principle that H19 modulates gene methylation
through SAHH, we performed global DNA methylation studies to
identify genes whose methylation might be affected in a way
similar to that of Nctc1. Mytotubes were transfected with siH19
(or siCon as a control), and DNA was extracted 48 h later and
subjected to genome-scale DNA methylation mapping using the
platform of an improved version of Reduced Representation
Bisulﬁte Sequencing. This platform offers detection of —three to
four million unique CpG sites, allowing 485% coverage of all
annotated CpG islands and 480% of all gene promoters for a
maximal amount of methylation data. It allows the identiﬁcation
and analysis of DMRs between samples at single-nucleotide
resolution. As expected, following H19 knockdown we observed
extensive genome-wide methylation pattern changes relative to
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siCon cells, with some genes showing increased methylation,
others showing decreased methylation and a third group with no
signiﬁcant change (Supplementary Fig. 6). We hypothesized that
in the group of genes showing increased methylation, some were
likely affected by increased activity of DNMT3B as a direct result
of SAHH activation. To test this possibility, we selected ﬁve
genes showing strong hypermethylation with siH19 (Supple-
mentary Data 1). Since SAHH dysfunction is associated with
human diseases8,10,11, we selected genes having important cellular
functions or implicated in diseases. Bmp8b (bone morphogenetic
protein 8b) has been reported to act as a signalling molecule in
energy balance regulation in both brown adipocytes and neurons,
and Bmp8b null mice exhibit decreased rate of metabolism and
impaired thermogenesis43. Casp2 (Caspase 2) is a member of the
caspase family that mediates cellular apoptosis through the
proteolytic cleavage of speciﬁc protein substrates44. In addition to
its well-deﬁned role in cell death, Casp2 has been implicated in
neurodegenerative diseases, tumorigenesis, metabolism and
aging44. Cdt1 (chromatin licensing and DNA replication factor
1) is a component of the prereplicative complex that assembles
on genomic DNA at origins of replication. Mutations in this
gene have been associated with growth failure in primordial
dwarﬁsm45. Foxa2 (forkhead box A2) is a DNA-binding trans-
cription factor essential for the development of endoderm-
derived organs including the liver and pancreas. Foxa2 has been
implicated in blood glucose homeostasis by controlling the
expression of multiple genes in pancreatic beta-cells46. Setd2
(SET domain containing 2) is a member of the SAM-dependent
histone lysine methyltransferase family (which also includes
EZH2, a component of PRC2) known to be important for
chromatin modiﬁcation2,47. SETD2 interacts with the
Huntington’s disease (HD) protein Huntingtin and has been
implicated in the pathogenesis of HD, a neurodegenerative
disorder characterized by loss of striatal neurons48.
To determine whether the increased methylation in these genes
as revealed by genome-wide analysis was SAHH-dependent,
myotubes were transfected with siH19 or siCon, with or without
co-transfection of siSahh or treatment of SAHH inhibitor DEA.
QMSP analysis was carried out 48 h post transfection using
primers that speciﬁcally amplify a single DMR of each respective
gene (Fig. 5a). While H19 knockdown increased DMR methyla-
tion, its combination with siSahh or DEA rescued methylation to
the level of the control (Fig. 5b). These results strongly suggested
H19-mediated, SAHH-dependent regulation of methylation at
these sites, thus validating our genome-wide data. To further
address whether DNMT3B might contribute to the increased
methylation, H19/Dnmt3b double knockdown experiments were
carried out, followed by QMSP analysis. As shown in Fig. 5c,
siH19 in combination with either Dnmt3b siRNA was able to
partially or fully restore methylation to the level of the siCon
control. The partial rescue by the Dnmt3b siRNAs suggested that
other DNMTs may contribute to the methylation of these sites,
which warrants future investigation. It is noteworthy that, while a
single DMR methylation change may seem small, the combined
effects from multiple DMRs in a single gene (Supplementary
Table 1 and Gene Expression Omnibus (GEO) accession number
GSE73014) could potentially be synergistic, leading to bigger
biological effects.
Next, DNMT3B ChIP analysis was conducted following siRNA
transfection (Fig. 6a). While no DNMT3B association was
detected at the DMRs of Cdt1 and Setd2, for the remaining three
genes tested, no change in DNMT3B occupancy at the respective
DMRs was observed following H19 knockdown (Fig. 6b). These
results supported the notion that the H19 knockdown-induced
increase in methylation was due to changes in DNMT3B activity
rather than its chromatin association.
H19 regulates gene expression via multiple mechanisms, both
in the nucleus and in the cytoplasm. Thus, H19 knockdown could
alter its nuclear interaction with methyl-CpG-binding domain
protein 1 and/or EZH2 to affect gene transcription23,27. In
the cytoplasm, H19 knockdown could change the dynamic
association of K homology-type splicing-regulatory protein with
its target mRNAs, leading to their stability changes28. The mRNA
levels of genes targeted by let-7 could also be affected, as H19 acts
as a molecular sponge for let-7 (ref. 29). Finally, H19 could
modulate transcription by affecting gene methylation through
interaction with SAHH (this report). Thus, the effects of H19
knockdown on genome-wide transcript levels would represent a
summation of contributions from the different mechanisms
outlined above as well as from other yet unknown mechanisms.
Consistent with this view, our RNA-sequencing (RNA-seq)
analysis revealed profound changes in transcript proﬁles
between siCon- and siH19-transfected myotubes (Supple-
mentary Data 2 and GEO accession number GSE73014). While
a number of these are consistent with alterations in DNA
methylation proﬁles, the multiplicity of H19 functions does not at
this time allow deﬁnitive mechanistic connections to be
established.
Discussion
This study uncovers a novel regulatory circuit of gene methyla-
tion dictated by the interaction between H19 and SAHH. Using
the Igf2-H19-Nctc1 gene locus in mouse muscle cells as a model,
we demonstrate that binding of SAHH to H19 interferes with its
ability to hydrolyse SAH, which is a potent product inhibitor of
SAM-dependent methyltransferases. This leads to decreased
DNMT3B-mediated methylation within the Nctc1 gene body
and subsequently reduced transcriptional activity of the Nctc1
promoter. We show that UREs in H19 that display preferential
binding to SAHH also inhibit the catalytic activity of SAHH,
suggesting that the basis for this preferential interaction is
recognition of the UREs. Further, we demonstrate that this H19–
SAHH-dependent regulation occurs at other genomic loci,
suggesting global effects of this regulation. On the basis of these
ﬁndings, we propose the model illustrated in Fig. 6c. To our
knowledge, this represents the ﬁrst case in which a single lncRNA
acts in trans to alter the epigenetic landscape in a genome-wide
manner.
Importantly, our ﬁndings offer novel insights into DNA
methylation regulation associated with development and patho-
logical conditions. Speciﬁcally, our results suggest that the
enzymatic activity of chromatin-bound DNMT3B might be
subjected to modiﬁcation by H19 through the H19/SAHH
pathway. Interestingly, DNMT3B (but not DNMT1) was shown
to be required for restoring demethylated genomic regions
induced by the methylation inhibitor 5-Aza-CdR (ref. 39).
Further, a recent genome-scale study comparing DNMT
occupation with DNA methylation patterns showed that a
fraction of gene loci bound by DNMTs does not overlap with
methylation and that the number of such loci changes
dramatically on cell differentiation1. It has been proposed that
loci bound by DNMTs, but which are not methylated, may be
primed for later de novo methylation events that are associated
with cell pluripotency and differentiation states1. It is possible
that the bound DNMTs are inactive because of inhibition (by yet
unknown mechanisms), which is removed as cell states change.
H19 expression is both temporally and spatially regulated during
development, and its aberrant expression has been linked to
human genetic disorders and cancer14,22. It is tempting to
postulate that the enzymatic activity of DNMTs might be
modulated in response to developmental cues and pathological
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conditions and that the H19–SAHH axis might be a functional
link underlying these regulations.
It has become increasingly evident that the relationship
between methylation and gene expression is far more complex
than previously thought. Unlike the classic models linking
promoter methylation to gene silencing and gene body methyla-
tion to expression, emerging models posit that the correlation
between methylation and gene expression is genomic context-
dependent1,3. Factors such as distance of CpGs relative to the
transcription start site, their residence in CpG islands, promoters,
enhancers or gene bodies as well as combinations of any of these
can positively or negatively affect gene expression. Thus, it is not
merely the sum or density of all methylated CpGs (which were
used to label a gene as being ‘hyper’ or ‘hypo’ methylated) but
rather the combinations of the various factors described above as
well as of other yet unknown factors that determine the outcome
on gene expression. Our studies reveal that H19 regulates
methylation at many genomic sites through modulating the
activity of SAHH. Further investigation will certainly unravel a
highly complex and context-dependent nature of this regulation.
Depending on cell/tissue types, developmental stages and
disease states, the biological end points of this H19/
SAHH-mediated regulation of gene methylation are likely to be
diverse. Curiously, the brain expresses very low or undetectable
levels of H19 (ref. 18) while accumulating uniquely high levels of
DNA hydroxymethylation (5-hydroxymethylcytosine) during
postnatal development49. Hydroxymethylation occurs through
oxidation of the methyl group of 5-methylcytosines by TET
enzymes, and this epigenetic modiﬁcation is thought to be
important for neuronal differentiation and function49–51. As
hydroxymethylation has been implicated in the active DNA
demethylation mechanism, it remains to be determined whether
the activity of SAHH in the brain might be signiﬁcantly lower or
the activity of SAHH might be subjected to regulation by
DMR sequences
chr4 123104670
Bmp8b
123104693
100% versus 0%
100% versus 15%
100% versus 14%
60% versus 33%
chr6 42265091 42265109
Casp2
chr8 122567821 122567844
Cdt1
chr2 148048955 148049050
Foxa2
chr9 110532285 110532307
Setd2
100% versus 92%
123104787
42265199
122567925
148049077
110532400
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
2.0
1.5
1.0
0.5
0.0
siCon siH19 siH19
+
siSahh
siH19
+
DEA
Casp2
* *
*
QMSP
Bmp8b
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
2.0
1.5
1.0
0.5
0.0
siCon siH19 siH19
+
siSahh
siH19
+
DEA
*
*
**
QMSP
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
2.0
1.5
1.0
0.5
0.0
siCon siH19 siH19
+
siDnmt3b
siH19
+
siDnmt3b-2
*
*
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siDnmt3b
siH19
+
siDnmt3b-2
0
1
2
3 *
*
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siDnmt3b
siH19
+
siDnmt3b-2
0
1
2
3
4
** **
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siDnmt3b
siH19
+
siDnmt3b-2
0
1
2
3
*
*
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siDnmt3b
siH19
+
siDnmt3b-2
0
1
2
3
4
** **
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siSahh
siH19
+
DEA
2.5
2.0
1.5
1.0
0.5
0.0
Cdt1
** **
**
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n 
siCon siH19 siH19
+
siSahh
siH19
+
DEA
2.5
2.0
1.5
1.0
0.5
0.0
Foxa2
** **
**
siCon siH19 siH19
+
siSahh
siH19
+
DEA
2.5
2.0
1.5
1.0
0.5
0.0
Setd2
R
el
at
ive
 
D
M
R
 
m
e
th
yla
tio
n
 
** **
**
b
c
a
Figure 5 | SAHH is required for H19-dependent methylation change in the DMRs of other genes. (a) Sequences of the DMRs of the indicated genes
ampliﬁed using QMSP primers. The differentially methylated cytosine residues are highlighted in red. Numbers above the sequences mark the positions of
the indicated nucleotides in the chromosomes. Numbers below (in blue) indicate percentage of methylation in the siH19 (left) versus siCon (right) cells as
determined by genome-wide methylation mapping. (b) Myotubes were transfected with siCon, siH19, siH19 plus siSahh or siH19 plus incubation with
10mM of DEA 20h post transfection. DNAs were isolated 48 h post transfection and analysed using QMSP. (c) Myotubes were transfected with siCon,
siH19, siH19 plus siDnmt3b or siH19 plus siDnmt3b-2. DNAs were isolated 48 h later and analysed using QMSP. Student’s t-tests were used to compare
differences between quantitative variables. Numbers are mean±s.d. (n¼ 3). **Po0.01, *Po0.05.
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non-H19-mediated mechanisms. Finally, as SAM-dependent
methyltransferases methylate other cellular components besides
DNA, our ﬁndings open up new avenues for future investigations
of other cellular components that might be regulated by the H19/
SAHH-dependent mechanism.
Methods
Reagents and plasmids. Mouse monoclonal anti-SAHH (Santa Cruz
Biotechnology, sc-271389), rabbit polyclonal anti-SAHH (Proteintech, 10757-2-AP),
mouse monoclonal anti-HuR (Santa Cruz, sc-5261), rabbit polyclonal anti-HuR
(Proteintech, 11910-1-AP), rabbit polyclonal anti-DNMT3B (Novus, NB300–516),
rabbit polyclonal anti-RNAP CTD repeat YSPTSPS (phospho S5; Abcam, ab5131),
rabbit polyclonal anti-b-tubulin (Abcam, ab6046), mouse monoclonal anti-b-actin
(Abcam, ab8226), mouse pre-immune IgGs (Chemicon, PP54) and rabbit
pre-immune IgGs (Thermo Scientiﬁc, Prod #1862244) were purchased. SiRNAs
speciﬁc for mouse H19 (siH19, 4390816/n253566), SAHH (siSahh, AM16708/
72248), Dnmt3b (siDnmt3b, AM16708/161533; siDnmt3b-2, 4390771/S65080) and
negative siCon (AM4636) were purchased from Ambion/Life Technologies. The
SAHH inhibitor DEA (sc-207632) was purchased from Santa Cruz. To construct
pH19, PCR was carried out using human term placental cDNA as a template
with forward 50-aaggaaaaaagcggccgcAGCAGGGTGAGGGAGGGGGTG-30
and reverse 50-cgcggatccGTAACAGTGTTTATTGATGATGAGTC-30 primers.
The lower-case letters represent restriction enzyme sites for NotI and BamHI,
respectively, and the upper-case letters are complementary to H19 sequence.
The resulting 2.6-kb-long PCR product was inserted into pFLAG-CMV-2 (Sigma)
opened with NotI and BamHI. To make pH19-S1, an annealed oligonucleotide
fragment containing a 44-nt-long S1 sequence (50-ACCGACCAGAATCATG
CAAGTGCGTAAGATAGTCGCGGGCCGGG-30) was cloned into pH19 at its
30-end opened with BamHI. pS1 was made by inserting the S1 sequence into
pFLAG-CMV-2 (Sigma) opened with NotI and BamHI.
Cell culture and transfection. HEK293 cells (ATCC, CRL-1573) were cultured
using standard protocols provided by the ATCC. Undifferentiated mouse C3H
myoblasts (Sigma-Aldrich, 91031101-iVL) were maintained in growth medium
(GM; DMEM, Gibco, 11965-092, supplemented with 10% fetal bovine serum, heat-
inactivated, 1% penicillin/streptomycin, 1% L-glutamine and 1-mM sodium pyr-
uvate). To prepare for differentiation, cells were seeded at a density of 1.6 105 or
1.0 104 cells per well in GM in 6- or 48-well plates, respectively. Differentiation
was initiated 2 days later when cells became conﬂuent by replacing GM with
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differentiation medium containing 2% horse serum in place of 10% fetal bovine
serum. The medium was changed every other day until transfection, which was
performed on days 3–4 after initiation of differentiation.
For cell transfection, mytotubes were washed once with pre-warmed
OPTI-MEM immediately before addition of transfection cocktails. To prepare
transfection cocktails for each well of six-well plates, 250 pmol of siCon or siH19
(with a stock solution of 5 mM) was mixed with 300 ml of OPTI-MEM by gentle
pipetting. In parallel, 12.5 ml of Lipofectamine 2000 was diluted in 300 ml of
OPTI-MEM by gentle pipetting. After 5-min incubation at room temperature, the
two were combined by gentle pipetting. Following incubation at room temperature
for 25min, the resulting cocktail (600 ml) was directly applied to myotubes that
were pre-washed with OPTI-MEM. After overnight incubation in a tissue culture
incubator, the cocktail was replaced with fresh differentiation medium. Forty-eight
hours later, RNA and protein were extracted for analysis.
RNA in situ hybridization and SAHH immunoﬂuorescence. Undifferentiated
myoblasts were seeded in m-Slide eight-well plates (Ibidi cat. no. 80826) at
B2 104 cells per well, and differentiation was initiated as described above. H19
RNA FISH experiments were carried out using the RNAscope ﬂuorescent
Multiplex system (Advanced Cell Diagnostic Inc.) according to the manufacturer’s
instructions. The protocol involves proteinase K treatment to remove
proteins including nucleases. The system included the following components:
Probe-Mm-H19-C3 (P/N: 423751-C3, L/N: 14241A; custom-designed speciﬁc
for mouse H19), Blank-C1 (P/N: 300041; L/N: 14132A), 3-Plex Negative Control
probe (P/N: 320371; L/N: 14105A), Pretreatment Kit-FL FF (P/N: 320842;
L/N: 14099A) and Detection Kit-FL (P/N: 320851; L/N: 14098A). For SAHH
immunostaining, myotubes were washed brieﬂy with TBS (20mM Tris-HCl,
pH 7.4, 225mM NaCl), ﬁxed with 3% paraformaldehyde/TBS for 20min,
permeabilized with 1% SDS/TBS for 5min and blocked with 10% BSA/0.1% goat
serum/TBS for 1 h. Cells were then incubated with polyclonal anti-SAHH antibody
at a dilution of 1:100 for 1 h, washed with TBS and then incubated with Alexa-488
secondary antibody (1:500 dilution, Invitrogen, Grand Island, NY) for 1 h.
After washing with TBS, cells were mounted with mounting medium containing
4,6-diamidino-2-phenylindole (Vector Lab, Burlingame, CA). Images were
obtained under the ﬂuorescence microscopy (Axiovert S 100; Carl Zeiss,
Oberkochen, Germany).
RNP afﬁnity puriﬁcation and protein identiﬁcation. HEK293 cells were
transfected with pH19-S1, pH19 or pS1 in a 25-cm plate scale and harvested 48 h
later by manual scraping and pelleted by centrifugation. After washing twice in
ice-cold PBS, cell pellet was resuspended in 1.2ml of ice-cold gentle lysis buffer
(GLB) (10mM Tris-HCl, pH 7.5; 10mM NaCl; 10mM EDTA; 0.5% Triton X-100;
1mM phenylmethylsulphonyl ﬂuoride (PMSF), 1 proteinase inhibitor cocktail
(CalBiochem, 539137); 1mM dithiothreitol (DTT) and 1 RNase inhibitor
(Roche, 10412600)) in a 1.5-ml eppendorf tube and incubated on ice for 20min.
Cell lysate was centrifuged to remove insoluble materials. The lysate was precleared
by incubation at 4 C for 1.5 h with 40ml of avidin agarose beads (Pierce, 20219)
with NaCl added to a ﬁnal concentration of 150mM. The cleared lysate was mixed
with 40 ml of streptavidin beads (packed volume, Sigma, S1638-5ML) and the tube
was rotated at 4 C for 3 h. The beads were collected and washed with 1ml of
ice-cold GLB plus (10mM Tris-HCl, pH 7.5; 150mM NaCl; 10mM EDTA; 0.5%
Triton X-100) ﬁve times by rotating the tube at 4 C for 3min each. The puriﬁed
RNPs were eluted from the beads in 20 ml of 2 SDS sample buffer by heating at
100 C for 5min and resolved by 10% SDS–PAGE. Following Commassie staining,
the protein band at 48 kDa in the pH19-S1 lane was excised and submitted for mass
spectrometry analysis by ProtTech Inc. (Norristown, PA 19403).
RIP analysis. To prepare antibodies, 20 ml of protein A Sepharose beads were
incubated with 20mg of monoclonal anti-SAHH antibody or 20 mg of mouse
pre-immune IgG in 500ml IP buffer (0.5% Triton X-100, 200mM NaCl, 10mM
Tris-HCl at pH 7.5 and 10mM EDTA) at 4 C overnight. The next day, the beads
were washed three times with IP buffer and kept on ice until used. To prepare cell
lysates, myotubes (from one well of a six-well plate) were harvested and cell pellets
resuspended in 600 ml of freshly prepared lysis buffer (0.5% Triton X-100, 10mM
NaCl, 10mM Tris-HCl at pH 7.5, 10mM EDTA, 0.5mM PMSF, 1mM DTT,
1 protease inhibitor cocktail (Calbiochem) and 400 units per ml RNase
inhibitor). The suspensions were incubated on ice for 20min. After removing
insoluble materials by centrifugation, lysates were precleared using 10 ml of protein
A sepharose (NaCl was added to a ﬁnal concentration of 200mM), followed by
addition of yeast tRNA (Ambion) to a ﬁnal concentration of 40 mgml 1. The
cleared lysates were transferred to tubes containing antibody or pre-immune
IgG-coated beads, and IP was carried out by rotating the tubes at 4 C for 3 h.
Following IP, the beads were washed ﬁve times with IP buffer by adding 1ml of the
buffer and rotating the tube at 4 C for 2min each time. RNA was extracted from
the beads using the PureLink RNA Mini Kit (Ambion, cat. no. 12183018A).
Reverse transcription was performed in a 40-ml reaction volume using the Bio-Rad
iScript cDNA synthesis kit, followed by quantitative PCR (qPCR).
Genomic DNA extraction. Genomic DNA was isolated using Quick-gDNA
MicroPrep (Zymo, D3021) according to the manufacturer’s instructions.
RNA extraction and RT–qPCR. Total RNAs were extracted from cells using the
PureLink RNA Mini Kit (Ambion, cat. no. 12183018A). cDNA was synthesized
using the Bio-Rad iSCRIPT kit (1725122) in a 20-ml reaction containing
100–500 ng of total RNA. Quantitative real-time PCR (RT–qPCR) was performed
in a 15-ml reaction containing 0.5–1 ml of cDNA using iQSYBRGreen (Bio-Rad) in
a Bio-Rad iCycler. PCR was performed by initial denaturation at 95 C for 5min,
followed by 40 cycles of 30 s at 95 C, 30 s at 60 C and 30 s at 72 C. Speciﬁcity was
veriﬁed using melting curve analysis and agarose gel electrophoresis. The threshold
cycle (Ct) values of each sample were used in the post-PCR data analysis. The
RT–PCR primers are listed in Supplementary Table 1.
Western blot analysis. Cell pellets were quickly lysed in ﬁve volumes of 2 SDS
sample buffer heated at 100 C for 5min, with occasional vortexing. Five to ten
microlitres of homogenized samples were loaded on 10% SDS gel, followed by
western blot analysis. The linear dynamic range of each protein of interest was
determined by serial dilutions. Bands on western blot gels were quantiﬁed using
ImageJ. Uncropped blots of Fig. 1c are shown in Supplementary Fig. 7.
QMSP analysis. Genomic DNA was extracted from myotubes in one well of
six-well plates using Quick-gDNA MicroPrep. Fifteen microlitres of water were
used to elute DNA from each column. For bisulﬁte treatment, 400–500 ng of DNA
was used for each column using the EZ DNA Methylation-Gold Kit (Zymo,
D5006). RT–qPCR was performed in a 15-ml reaction containing 1 ml of the eluant
using iQSYBRGreen (Bio-Rad) in a Bio-Rad iCycler. The PCR primers
(Supplementary Table 2) for methylated DNA were used at a ﬁnal concentration of
0.3 mM in each PCR reaction. PCR was performed by initial denaturation at 95 C
for 5min, followed by 40 cycles of 30 s at 95 C, 30 s at 60 C and 30 s at 72 C.
Speciﬁcity was veriﬁed using melting curve analysis and agarose gel electrophoresis.
The Ct values of each sample were used in the post-PCR data analysis. Albumin
DNA was used as loading controls for all QMSP normalization.
In vivo SAHH activity assay. The experiments were performed in a 96-well scale
using the Mouse Homocysteine (Hcy) ELISA Kit (Mybiosource, MBS260152) that
allows quantitative measurement of homocysteine concentration in cell
extracts, according to the manufacturer’s instructions. The concentration of
homocysteine in cell extracts was used as a readout for in vivo SAHH activity37,
as SAHH hydrolyses SAH to homocysteine and adenosine. Brieﬂy, myotubes
were washed with cold PBS and lysed on plate in 200ml of lysis buffer (40mM
hexadecyltrimethylammonium bromide, 75mM Tris-HCl, pH 8.0, 1M NaCl,
15mM EDTA). The lysate was cleared of insoluble materials by centrifugation at
15,000g at 4 C for 15min. Immediately following the centrifugation, 100 ml of the
supernatant was collected and used for SAHH activity measurement. The
absorbance of the samples was determined using a FilterMax F3&F5 Multi-Mode
Microplate Reader (Molecular Devices). A serial dilution of mouse Hcy was
included in each assay to obtain a standard curve. The assay was performed in
triplicate. The concentrations of DNA and RNA extracted from parallel wells were
used as loading controls for SAHH activity normalization.
ChIP. These experiments were performed in a six-well plate scale using the Pierce
Agarose ChIP Kit (Thermo Scientiﬁc, 26156) according to the manufacturer’s
instructions with minor modiﬁcations. Brieﬂy, myotubes were detached from plates
in 0.25% Trypsin-EDTA and transferred to a 1.5-ml tube. Crosslinking was
performed in 1% formaldehyde at room temperature for 10min, and the reaction
was stopped by glycine. ChIPs using anti-Ser-5(P)-RNAP or anti-DNMT3B
antibodies (or rabbit pre-immune IgGs as a negative control) were carried out
overnight at 4 C. Levels of ChIP-puriﬁed DNA were determined with RT–qPCR
(see Supplementary Table 3 for primer sequences). The relative enrichments of the
indicated DNA regions were calculated using the Percent Input Method according
to the manufacturer’s instructions.
Production of RNA fragments for in vitro analyses. Zymo Taq DNA polymerase
(Zymo Research, E2001) was used to amplify hURE (128 nucleotide (nt)), mURE
(122 nt) and hNSE (131 nt) using plasmid DNA containing human29 or mouse
(accession no. NR_001592) H19 sequences as PCR templates. All forward primers
contained a T7 promoter sequence (Supplementary Table 4). The PCR products
were puriﬁed using Zymo DNA clean and concentrator kit (Zymo Research,
D4003) and used as templates for subsequent in vitro transcription. RNA
fragments for EMSA and in vitro rSAHH activity analysis were generated by
in vitro transcription using the T7 MEGAscript Kit (Ambion, AM1334). The
resulting RNA was lithium chloride precipitated and the quality of the RNA was
conﬁrmed using electrophoresis. The RNA 30 End Biotinylation Kit (Thermo
Scientiﬁc, 20160) was used to make 30-end biotin-labelled RNA fragments,
according to the manufacturer’s instructions. The biotin-labelled RNA fragments
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were extracted with phenol:chloroform and precipitated with 70% ethanol. Puriﬁed
RNA fragments were aliquoted and stored at  80 C until use.
EMSA. Binding reactions were carried out in 20 ml containing 5 nM of 30-end
biotin-labelled RNA, together with indicated amounts of Escherichia coli-expressed,
puriﬁed rSAHH, (Creative BioMart, AHCY-31342TH). Binding buffer contained
5mM Tris-HCl, pH 7.4, 5mM MgCl2, 3% (v/v) glycerol, 100mM NaCl, 1mM
DTT, 1 proteinase inhibitor cocktail (CalBiochem, 539137) and 1 RNase
inhibitor (Roche, 10412600)). Before mixing with the rest of the components in the
binding reaction, RNA was heated at 90 C for 3min, followed by immediate chill
on ice until use. Binding reaction was conducted at 25 C for 30min. At the
end of incubation, 5 ml of loading buffer was added and samples loaded on 4%
native polyacrylamide gels (Bio-Rad mini protein gel size), which had been
pre-electrophoresed at 4 C for 60min in 0.5 Tris-borate-EDTA. Electrophoresis
was carried out at 4 C at 140V for 75min. Following electrophoresis, components
in the gels were transferred to Amersham Hybond-Nþ nylon membrane
(GE Healthcare, RPN303B) in 0.5 Tris-borate-EDTA at 400mA for 38min at
4 C. The membrane was then crosslinked with ultraviolet light (254 nm) for 4min
at a distance of 0.5 cm. Signals were developed using LightShift chemiluminescent
EMSA kit (Thermo Scientiﬁc, 89880) according to the manufacturer’s instructions.
For EMSA competition assays, rSAHH protein and labelled hURE RNA were
added to a 20-ml reaction at ﬁnal concentrations of 2 mM and 5 nM, respectively.
Unlabelled hURE, mURE, hNSE and poly(U) (Sigma-Aldrich, P9528-10MG) were
added at the indicated molar excess, followed by incubation and electrophoresis, as
described above.
Band intensities of scanned ﬁlms were quantiﬁed using the ImageJ software,
and the data processed using the GraphPad Prism programme (Version 6.0f). The
per cent bound RNA was determined as follows: [% bound complex¼ (bound
probe background)/(total probe background) 100]. All experiments
contained a control reaction lacking rSAHH. Kd was calculated using nonlinear
regression analysis performed with the Prism 6.0f software. Kd is the dissociation
constant. Signals of complexes 1 and 2 were combined to generate probe-bound
signals in Kd calculation.
In vitro rSAHH activity assays. These experiments were designed to test whether
binding of H19 RNA fragments to rSAHH would inhibit rSAHH enzymatic activity
in vitro. The experiments were performed using the Adenosylhomocysteinase
Activity Fluorometric Assay Kit (Biovision, K807-100) according to the
manufacturer’s instructions. This kit allows quantitative detection of adenosine
concentration as a readout for rSAHH’s ability to hydrolyse SAH in vitro. Brieﬂy,
2mg of rSAHH was pre-incubated with unlabelled RNA fragments (preheated at
90 C for 3min and then chilled on ice before use) in AHCY assay buffer in a total
volume of 20 ml at room temperature for 20min. At the end of incubation, an
additional 30ml of AHCY assay buffer was added, followed by addition of 50 ml of
reagents containing SAH. The resulting 100 ml reaction mixture was immediately
subjected to absorbance reading using a kinetic mode in a FilterMax F3&F5 Multi-
Mode Microplate Reader (Molecular Devices). In the ﬁnal 100-ml reaction mixture,
the concentration of rSAHH was 0.4mM, and those of the RNA fragments were 0,
0.2 and 1 nM. Relative rSAHH activities are presented with those in the absence of
the RNA fragments arbitrarily set as 1.
Methyl-MiniSeq library construction. Libraries were prepared from 200 to
500 ng of genomic DNA digested with 60 units of TaqaI and 30 units of MspI
(NEB) sequentially and then extracted with Zymo Research DNA Clean &
Concentrator-5 kit (Cat. no. D4003). Fragments were ligated to pre-annealed
adapters containing 50-methyl-cytosine instead of cytosine according to the
Illumina’s speciﬁed guidelines (www.illumina.com). Adaptor-ligated fragments of
150–250 and 250–350 bp in size were recovered from a 2.5% NuSieve 1:1 agarose
gel (Zymoclean Gel DNA Recovery Kit, Zymo Research Cat. no. D4001). The
fragments were then bisulﬁte-treated using the EZ DNA Methylation-Lightning Kit
(Zymo Research, Cat. no.D5020). Preparative-scale PCR was performed and the
resulting products were puriﬁed (DNA Clean & Concentrator, Zymo Research,
Cat. no.D4005) for sequencing on an Illumina HiSeq.
Methyl-MiniSeq Sequence alignments and data analysis. Sequence reads
from bisulﬁte-treated EpiQuest libraries were identiﬁed using standard
Illumina base-calling software and then analysed using a Zymo Research
proprietary analysis pipeline, which is written in Python and used Bismark
(http://www.bioinformatics.babraham.ac.uk/projects/bismark/) to perform the
alignment. Index ﬁles were constructed using the bismark_genome_preparation
command and the entire reference genome. The non_directional parameter was
applied while running Bismark. All other parameters were set to default. Filled-in
nucleotides were trimmed off when doing methylation calling. The methylation
level of each sampled cytosine was estimated as the number of reads reporting a C,
divided by the total number of reads reporting a C or T. Fisher’s exact test or t-test
was performed for each CpG site, which has at least ﬁve reads coverage, and
promoter, gene body and CpG island annotations were added for each CpG
included in the comparison.
RNA-seq and data analysis. Mouse C3H myoblasts were maintained in six-well
plates. Myotubes were transfected with siCon or siH19 in triplicates for 40 h
following initiation of differentiation. Cells were harvested for RNA extraction 48 h
post transfection using the Purelink RNA mini kit (Cat. no. 12183018A). RNA-seq
libraries were prepared using the Illumina TruSeq Stranded Total RNA LT kit with
Ribo-Zero Human/Mouse/Rat, setA (Cat. no. rs-122–2201) according to the
sample preparation protocol. Brieﬂy, 1 mg total RNA was subjected to Ribo-Zero
depletion to remove rRNAs. The remaining RNA was puriﬁed, fragmented and
primed with random hexamers for cDNA synthesis. After ﬁrst and second cDNA
synthesis, cDNA fragments were adenylated and then ligated to indexing adapters.
The cDNA fragments were enriched by PCR, puriﬁed and then sequenced on an
Illumina NextSeq500 using paired-end chemistry and 76-bp cycles. Sequences are
available from the GEO with accession number GSE73014.
Illumina BaseSpace (https://basespace.illumina.com/)-embedding tools were
used to analyse the RNA-seq data. TopHat Alignment 1.0.0 app was used to map
sequencing reads to mm10 genome. Cufﬂinks Assembly & DE 1.0.0 app containing
Cufﬂinks 2.1.1 and Cuffdiff 2.1.1 was applied to assemble mapped transcripts and
calculate differential expression of genes and transcripts.
Statistical analysis. All data (unless otherwise indicated) are presented as
mean±s.d. Statistical analyses were performed using the Statistical Package for the
Social Science computer software version 17.0 (IBM SPSS Statistics, Chicago, IL,
USA). The Student’s t-test was used to compare differences between quantitative
variables. The Fisher’s exact text was used when appropriate, for comparing
categorical variables (contingency tables). P values at 0.05 or smaller were
considered signiﬁcant.
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